- AustraliaNorth AmericaWorld
Investing News NetworkYour trusted source for investing success
- Lithium Outlook
- Oil and Gas Outlook
- Gold Outlook Report
- Uranium Outlook
- Rare Earths Outlook
- All Outlook Reports
- Top Generative AI Stocks
- Top EV Stocks
- Biggest AI Companies
- Biggest Blockchain Stocks
- Biggest Cryptocurrency-mining Stocks
- Biggest Cybersecurity Companies
- Biggest Robotics Companies
- Biggest Social Media Companies
- Biggest Technology ETFs
- Artificial Intellgience ETFs
- Robotics ETFs
- Canadian Cryptocurrency ETFs
- Artificial Intelligence Outlook
- EV Outlook
- Cleantech Outlook
- Crypto Outlook
- Tech Outlook
- All Market Outlook Reports
- Cannabis Weekly Round-Up
- Top Alzheimer's Treatment Stocks
- Top Biotech Stocks
- Top Plant-based Food Stocks
- Biggest Cannabis Stocks
- Biggest Pharma Stocks
- Longevity Stocks to Watch
- Psychedelics Stocks to Watch
- Top Cobalt Stocks
- Small Biotech ETFs to Watch
- Top Life Science ETFs
- Biggest Pharmaceutical ETFs
- Life Science Outlook
- Biotech Outlook
- Cannabis Outlook
- Pharma Outlook
- Psychedelics Outlook
- All Market Outlook Reports
Rocket Pharmaceuticals Announces Data from Phase 1/2 Trial of RP-L102
Rocket Pharmaceuticals (NASDAQ:RCKT) has announced the publication of long-term data from its ongoing Phase 1/2 trial of RPL-102, the company’s lentiviral vector (LVV)-based gene therapy in the journal Nature Medicine. As quoted in the press release: The data included in the manuscript are from the first four patients treated with RP-L102 in the Phase 1/2 …
Rocket Pharmaceuticals (NASDAQ:RCKT) has announced the publication of long-term data from its ongoing Phase 1/2 trial of RPL-102, the company’s lentiviral vector (LVV)-based gene therapy in the journal Nature Medicine.
As quoted in the press release:
The data included in the manuscript are from the first four patients treated with RP-L102 in the Phase 1/2 FANCOLEN-I trial that utilized first-generation “Process A” without the use of any conditioning regimen. Follow-up for each of the initial four patients was 18-30 months from administration of RP-L102.
“Data from our first trial of RP-L102 demonstrate increasing levels of bone marrow engraftment, leading to stabilization and restored bone marrow function. These data highlight the natural selective advantage that uniquely exists in FA for gene corrected stem cells over diseased stem cells, which potentially obviates the need for conditioning,” said Jonathan Schwartz, M.D., Chief Medical Officer and Senior Vice President of Rocket. “At the end of the year, we will have a first look at initial data from our Phase 1 trial of ‘Process B’ RP-L102, which utilizes fresh cells and incorporates a modified stem cell enrichment process, transduction enhancers, and commercial-grade vector and final drug product. We are also excited by the prospect of starting our global registrational trial incorporating recent alignment on endpoints from both the U.S. Food and Drug Administration and European Medicines Agency.”
“There is an increased and urgent need for new therapies for patients and families suffering from FA as current treatments are limited to toxic and burdensome bone marrow transplant,” said Paula Río, Ph.D., Senior Scientist, División de Terapias Innovadoras en el Sistema Hematopoyético, CIEMAT/CIBERER Unidad Mixta de Terapias Avanzadas CIEMAT/IIS Fundación Jiménez Díaz, and co-first author of the manuscript. “We are very pleased to see long-term follow-up data that further support our thesis for RP-L102 gene therapy without any conditioning to serve as an innovative, low-toxicity treatment for the hematologic component of this devastating disease.”
Latest News
Investing News Network websites or approved third-party tools use cookies. Please refer to the cookie policy for collected data, privacy and GDPR compliance. By continuing to browse the site, you agree to our use of cookies.